News

FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication

Publish date: February 10, 2014

 

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Diabetes morbidity varies with patient age, disease duration
MDedge Internal Medicine
Mild coronary artery disease is gender blind
MDedge Internal Medicine
Higher PCI risk in diabetes not due to insulin
MDedge Internal Medicine
FDA panel backs approval of novel antiplatelet drug vorapaxar
MDedge Internal Medicine
FDA panel rejects rivaroxaban again for acute coronary syndrome
MDedge Internal Medicine
Surgeon General report links smoking to diseases beyond cancer
MDedge Internal Medicine
Inpatient safety efforts yield mixed results
MDedge Internal Medicine
Cooling the resuscitated sudden dead
MDedge Internal Medicine
FDA: Naproxen may pose lower CV risk
MDedge Internal Medicine
Persistent depression doubled coronary heart disease risk
MDedge Internal Medicine

Related Articles